These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 17487785

  • 1. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic.
    Shah AR, Scher L.
    IDrugs; 2007 May; 10(5):329-35. PubMed ID: 17487785
    [Abstract] [Full Text] [Related]

  • 2. Alfimeprase.
    Drugs R D; 2008 May; 9(3):185-90. PubMed ID: 18457471
    [Abstract] [Full Text] [Related]

  • 3. Fibrolase: trials and tribulations.
    Markland FS, Swenson S.
    Toxins (Basel); 2010 Apr; 2(4):793-808. PubMed ID: 22069611
    [Abstract] [Full Text] [Related]

  • 4. A phase I trial of alfimeprase for peripheral arterial thrombolysis.
    Ouriel K, Cynamon J, Weaver FA, Dardik H, Akers D, Blebea J, Gruneiro L, Toombs CF, Wang-Clow F, Mohler M, Pena L, Wan CY, Deitcher SR.
    J Vasc Interv Radiol; 2005 Aug; 16(8):1075-83. PubMed ID: 16105919
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.
    Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR.
    J Clin Oncol; 2006 Jul 01; 24(19):3056-60. PubMed ID: 16809729
    [Abstract] [Full Text] [Related]

  • 6. Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase.
    Deitcher SR, Toombs CF.
    Pathophysiol Haemost Thromb; 2005 Jul 01; 34(4-5):215-20. PubMed ID: 16707931
    [Abstract] [Full Text] [Related]

  • 7. Alfimeprase: a novel recombinant direct-acting fibrinolytic.
    Deitcher SR, Funk WD, Buchanan J, Liu S, Levy MD, Toombs CF.
    Expert Opin Biol Ther; 2006 Dec 01; 6(12):1361-9. PubMed ID: 17223743
    [Abstract] [Full Text] [Related]

  • 8. Hirudin and s18886 maintain luminal patency after thrombolysis with alfimeprase.
    Lee JY, Markland FS, Lucchesi BR.
    J Cardiovasc Pharmacol; 2013 Feb 01; 61(2):152-9. PubMed ID: 23188127
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO).
    Han SM, Weaver FA, Comerota AJ, Perler BA, Joing M.
    J Vasc Surg; 2010 Mar 01; 51(3):600-9. PubMed ID: 20110153
    [Abstract] [Full Text] [Related]

  • 10. Alfimeprase for the treatment of acute peripheral arterial occlusion.
    Moise MA, Kashyap VS.
    Expert Opin Biol Ther; 2008 May 01; 8(5):683-9. PubMed ID: 18407770
    [Abstract] [Full Text] [Related]

  • 11. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis.
    Toombs CF.
    Haemostasis; 2001 May 01; 31(3-6):141-7. PubMed ID: 11910179
    [Abstract] [Full Text] [Related]

  • 12. Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion.
    Lu A, Kurosawa Y, Luskey K, Pyne-Geithman G, Caudell D, Clark J.
    Neurol Res; 2009 Mar 01; 31(2):209-14. PubMed ID: 19298764
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of action and thrombolytic potential of staphylokinase.
    Lijnen HR.
    Verh K Acad Geneeskd Belg; 1995 Mar 01; 57(4):303-14. PubMed ID: 8571666
    [Abstract] [Full Text] [Related]

  • 14. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E, Szemraj J, Malinowski M, Rozpończyk J.
    Postepy Biochem; 2006 Mar 01; 52(1):80-6. PubMed ID: 16869305
    [Abstract] [Full Text] [Related]

  • 15. Plasminogen activators: a comparison.
    Baruah DB, Dash RN, Chaudhari MR, Kadam SS.
    Vascul Pharmacol; 2006 Jan 01; 44(1):1-9. PubMed ID: 16275118
    [Abstract] [Full Text] [Related]

  • 16. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
    Cosmi B.
    Curr Opin Mol Ther; 2009 Jun 01; 11(3):322-8. PubMed ID: 19479665
    [Abstract] [Full Text] [Related]

  • 17. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.
    Marder VJ, Novokhatny V.
    J Thromb Haemost; 2010 Mar 01; 8(3):433-44. PubMed ID: 19943877
    [Abstract] [Full Text] [Related]

  • 18. Invited commentary. Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO).
    Kashyap VS.
    J Vasc Surg; 2010 Mar 01; 51(3):609. PubMed ID: 20206805
    [No Abstract] [Full Text] [Related]

  • 19. Alfimeprase to succeed Genentech's alteplase?
    Vastag B.
    Nat Biotechnol; 2006 Aug 01; 24(8):875-6. PubMed ID: 16900112
    [No Abstract] [Full Text] [Related]

  • 20. Alpha-fibrinogenases.
    Swenson S, Toombs CF, Pena L, Johansson J, Markland FS.
    Curr Drug Targets Cardiovasc Haematol Disord; 2004 Dec 01; 4(4):417-35. PubMed ID: 15578961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.